Kuros Biosciences obtains clearance to market in the U.S. and New Zealand

31 January 2024 12:02

Zurich CCGreater ZurichSwiss AMCHAM SoCal

Schlieren - Kuros Biosciences from the canton of Zurich has received clearance in the U.S. for MagnetOs Granules for interbody use. The authorities in New Zealand have issued clearance for MagnetOs Granules and MagnetOs Putty.

Schlieren-based Kuros Biosciences AG has received clearance to market from the U.S. Food and Drug Administration (FDA) for MagnetOs Granules for interbody use, according to a press release. This makes MagnetOs Granules the third product from the MagnetOs portfolio to obtain FDA clearance to market for interbody use. At the start of January, Kuros announced that it had received FDA clearance for MagnetOs Easypack Putty for interbody use and MagnetOs Putty for standalone use in the posterolateral spine, which means that it can now be used without autograft (patient’s own bone).

Kuros has also announced clearance to market in New Zealand for MagnetOs Granules and MagnetOs Putty. The products are now commercially available via Vortek Spine Limited (Vortek), a high tech company for orthopaedics and biology located in Christchurch, New Zealand.

“We are very pleased that MagnetOs Granules has received marketing clearance for interbody use given the Granules technology is the foundation of the MagnetOs platform,” says Chris Fair, CEO of Kuros Biosciences. “This clearance, coupled with the MagnetOs Flex Matrix and MagnetOs Easypack Putty formulations, provides our surgeons the widest variety of advanced biologic formulations available for use in the interbody space.” Kuros is expanding its international presence through the partnership with Vortek in New Zealand, to introduce its clinically proven technology to this region.

Kuros Biosciences AG is a spin-off from the University of Zurich and Swiss Federal Institute of Technology in Zurich. The company is based in the Bio-Technopark Schlieren-Zürich. ce/gba

Swiss Pavilion Digital

Previous newsletters